Zonisamide in the management of epilepsy in the elderly

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.

Original languageEnglish
Pages (from-to)931-937
Number of pages7
JournalClinical Interventions in Aging
Volume10
DOIs
Publication statusPublished - Jun 8 2015

Fingerprint

zonisamide
Epilepsy
Anticonvulsants
Partial Epilepsy
Therapeutics
Observational Studies
Seizures
Randomized Controlled Trials
Clinical Trials
Safety

Keywords

  • Efficacy
  • Elderly
  • Epilepsy
  • Safety
  • Zonisamide

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Zonisamide in the management of epilepsy in the elderly. / Romigi, Andrea; Femia, Eti A.; Fattore, Cinzia; Vitrani, Giuseppe; Di Gennaro, Giancarlo; Franco, Valentina.

In: Clinical Interventions in Aging, Vol. 10, 08.06.2015, p. 931-937.

Research output: Contribution to journalArticle

@article{aa0b83e0ff8b4e85a754630792ca3f03,
title = "Zonisamide in the management of epilepsy in the elderly",
abstract = "Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.",
keywords = "Efficacy, Elderly, Epilepsy, Safety, Zonisamide",
author = "Andrea Romigi and Femia, {Eti A.} and Cinzia Fattore and Giuseppe Vitrani and {Di Gennaro}, Giancarlo and Valentina Franco",
year = "2015",
month = "6",
day = "8",
doi = "10.2147/CIA.S50819",
language = "English",
volume = "10",
pages = "931--937",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Zonisamide in the management of epilepsy in the elderly

AU - Romigi, Andrea

AU - Femia, Eti A.

AU - Fattore, Cinzia

AU - Vitrani, Giuseppe

AU - Di Gennaro, Giancarlo

AU - Franco, Valentina

PY - 2015/6/8

Y1 - 2015/6/8

N2 - Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.

AB - Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.

KW - Efficacy

KW - Elderly

KW - Epilepsy

KW - Safety

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=84935841389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935841389&partnerID=8YFLogxK

U2 - 10.2147/CIA.S50819

DO - 10.2147/CIA.S50819

M3 - Article

AN - SCOPUS:84935841389

VL - 10

SP - 931

EP - 937

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -